Titre : Récepteurs activés par la protéinase

Récepteurs activés par la protéinase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognitive Dysfunction
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Récepteurs activés par la protéinase : Questions médicales les plus fréquentes", "headline": "Récepteurs activés par la protéinase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Récepteurs activés par la protéinase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-26", "dateModified": "2025-03-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Récepteurs activés par la protéinase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteurs de surface cellulaire", "url": "https://questionsmedicales.fr/mesh/D011956", "about": { "@type": "MedicalCondition", "name": "Récepteurs de surface cellulaire", "code": { "@type": "MedicalCode", "code": "D011956", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Récepteur de type PAR-2", "alternateName": "Receptor, PAR-2", "url": "https://questionsmedicales.fr/mesh/D044464", "about": { "@type": "MedicalCondition", "name": "Récepteur de type PAR-2", "code": { "@type": "MedicalCode", "code": "D044464", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.792.249" } } }, { "@type": "MedicalWebPage", "name": "Récepteurs à la thrombine", "alternateName": "Receptors, Thrombin", "url": "https://questionsmedicales.fr/mesh/D018179", "about": { "@type": "MedicalCondition", "name": "Récepteurs à la thrombine", "code": { "@type": "MedicalCode", "code": "D018179", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.792.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Récepteur de type PAR-1", "alternateName": "Receptor, PAR-1", "url": "https://questionsmedicales.fr/mesh/D044463", "about": { "@type": "MedicalCondition", "name": "Récepteur de type PAR-1", "code": { "@type": "MedicalCode", "code": "D044463", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.792.500.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Récepteurs activés par la protéinase", "alternateName": "Receptors, Proteinase-Activated", "code": { "@type": "MedicalCode", "code": "D044462", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Rithwik Ramachandran", "url": "https://questionsmedicales.fr/author/Rithwik%20Ramachandran", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada." } }, { "@type": "Person", "name": "Brice Korkmaz", "url": "https://questionsmedicales.fr/author/Brice%20Korkmaz", "affiliation": { "@type": "Organization", "name": "INSERM U-1100, \"Centre d'Etude des Pathologies Respiratoires\" and Université François Rabelais, 37032, Tours, France." } }, { "@type": "Person", "name": "Arundhasa Chandrabalan", "url": "https://questionsmedicales.fr/author/Arundhasa%20Chandrabalan", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada." } }, { "@type": "Person", "name": "Carlotta Lambertini", "url": "https://questionsmedicales.fr/author/Carlotta%20Lambertini", "affiliation": { "@type": "Organization", "name": "Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy." } }, { "@type": "Person", "name": "Augusta Zannoni", "url": "https://questionsmedicales.fr/author/Augusta%20Zannoni", "affiliation": { "@type": "Organization", "name": "Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Independent replication of advanced brain age in mild cognitive impairment and dementia: detection of future cognitive dysfunction.", "datePublished": "2022-08-16", "url": "https://questionsmedicales.fr/article/35974140", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41380-022-01728-y" } }, { "@type": "ScholarlyArticle", "name": "[Immunological mechanisms of cognitive dysfunction under systemic therapy in metastatic melanoma].", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36350371", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00105-022-05070-w" } }, { "@type": "ScholarlyArticle", "name": "Polysomnographic Predictors of Sleep, Motor, and Cognitive Dysfunction Progression in Parkinson's Disease.", "datePublished": "2022-08-22", "url": "https://questionsmedicales.fr/article/35994190", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11910-022-01226-2" } }, { "@type": "ScholarlyArticle", "name": "Acute disease induced cognitive dysfunction in older patients - an unrecognized syndrome.", "datePublished": "2022-08-15", "url": "https://questionsmedicales.fr/article/35971082", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12877-022-03323-w" } }, { "@type": "ScholarlyArticle", "name": "Effects of Dexmedetomidine Anesthesia on Early Postoperative Cognitive Dysfunction in Elderly Patients.", "datePublished": "2022-07-21", "url": "https://questionsmedicales.fr/article/35864562", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acschemneuro.2c00173" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs activés par la protéinase", "item": "https://questionsmedicales.fr/mesh/D044462" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Récepteurs activés par la protéinase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Récepteurs activés par la protéinase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Récepteurs activés par la protéinase", "description": "Comment diagnostiquer une activation des récepteurs par protéinase ?\nQuels tests sont utilisés pour évaluer ces récepteurs ?\nLes examens d'imagerie sont-ils utiles ?\nQuels symptômes peuvent indiquer une activation anormale ?\nY a-t-il des marqueurs spécifiques à rechercher ?", "url": "https://questionsmedicales.fr/mesh/D044462?mesh_terms=Cognitive+Dysfunction&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Récepteurs activés par la protéinase", "description": "Quels sont les symptômes d'une activation excessive ?\nComment l'activation affecte-t-elle le système immunitaire ?\nPeut-on observer des symptômes neurologiques ?\nQuels signes cliniques sont associés à ces récepteurs ?\nL'activation peut-elle causer des symptômes respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D044462?mesh_terms=Cognitive+Dysfunction&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Récepteurs activés par la protéinase", "description": "Comment prévenir l'activation des récepteurs ?\nL'alimentation joue-t-elle un rôle préventif ?\nLe mode de vie influence-t-il l'activation ?\nDes vaccinations peuvent-elles aider ?\nLe suivi médical est-il important ?", "url": "https://questionsmedicales.fr/mesh/D044462?mesh_terms=Cognitive+Dysfunction&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Récepteurs activés par la protéinase", "description": "Quels traitements ciblent les récepteurs activés par protéinase ?\nLes anti-inflammatoires sont-ils efficaces ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la physiothérapie peut-elle aider ?\nLes traitements naturels sont-ils recommandés ?", "url": "https://questionsmedicales.fr/mesh/D044462?mesh_terms=Cognitive+Dysfunction&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Récepteurs activés par la protéinase", "description": "Quelles complications peuvent survenir ?\nL'activation peut-elle entraîner des cancers ?\nY a-t-il des complications cardiovasculaires ?\nComment l'activation affecte-t-elle la santé mentale ?\nDes complications respiratoires sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D044462?mesh_terms=Cognitive+Dysfunction&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Récepteurs activés par la protéinase", "description": "Quels sont les principaux facteurs de risque ?\nLe tabagisme est-il un facteur de risque ?\nLe stress peut-il influencer l'activation ?\nY a-t-il un lien avec l'obésité ?\nLes maladies auto-immunes augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D044462?mesh_terms=Cognitive+Dysfunction&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une activation des récepteurs par protéinase ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests biologiques et l'analyse des symptômes cliniques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer ces récepteurs ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'immunohistochimie et des dosages de biomarqueurs peuvent être utilisés." } }, { "@type": "Question", "name": "Les examens d'imagerie sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à visualiser des anomalies associées, mais n'est pas spécifique." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une activation anormale ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'inflammation ou la douleur peuvent indiquer une activation anormale." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques à rechercher ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme les cytokines peuvent indiquer une activation des récepteurs." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une activation excessive ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, inflammation, et dysfonctionnement des organes." } }, { "@type": "Question", "name": "Comment l'activation affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner une réponse immunitaire exacerbée, provoquant des maladies auto-immunes." } }, { "@type": "Question", "name": "Peut-on observer des symptômes neurologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activation peut affecter le système nerveux, entraînant des troubles neurologiques." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à ces récepteurs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'œdème et la rougeur peuvent être observés lors de l'activation." } }, { "@type": "Question", "name": "L'activation peut-elle causer des symptômes respiratoires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des symptômes comme la dyspnée ou l'asthme." } }, { "@type": "Question", "name": "Comment prévenir l'activation des récepteurs ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les facteurs déclenchants comme le stress et les infections peut aider." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle préventif ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en antioxydants peut réduire le risque d'activation." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il l'activation ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain avec exercice régulier peut diminuer le risque." } }, { "@type": "Question", "name": "Des vaccinations peuvent-elles aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui déclenchent l'activation." } }, { "@type": "Question", "name": "Le suivi médical est-il important ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de détecter précocement les signes d'activation." } }, { "@type": "Question", "name": "Quels traitements ciblent les récepteurs activés par protéinase ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques et des anticorps monoclonaux peuvent être utilisés." } }, { "@type": "Question", "name": "Les anti-inflammatoires sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire l'inflammation causée par l'activation des récepteurs." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux en cours ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblés sont en phase d'essai clinique." } }, { "@type": "Question", "name": "Comment la physiothérapie peut-elle aider ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut améliorer la fonction physique et réduire la douleur associée à l'activation." } }, { "@type": "Question", "name": "Les traitements naturels sont-ils recommandés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certains traitements naturels peuvent aider, mais doivent être discutés avec un médecin." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des maladies inflammatoires chroniques peuvent se développer." } }, { "@type": "Question", "name": "L'activation peut-elle entraîner des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une activation prolongée est associée à un risque accru de certains cancers." } }, { "@type": "Question", "name": "Y a-t-il des complications cardiovasculaires ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activation peut contribuer à des maladies cardiovasculaires et des AVC." } }, { "@type": "Question", "name": "Comment l'activation affecte-t-elle la santé mentale ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être liée à des troubles de l'humeur et à l'anxiété." } }, { "@type": "Question", "name": "Des complications respiratoires sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activation peut aggraver des conditions comme l'asthme ou la BPCO." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les antécédents familiaux et les infections chroniques." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque d'activation des récepteurs et de maladies associées." } }, { "@type": "Question", "name": "Le stress peut-il influencer l'activation ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique est un facteur de risque connu pour l'activation des récepteurs." } }, { "@type": "Question", "name": "Y a-t-il un lien avec l'obésité ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est associée à une inflammation chronique et à l'activation des récepteurs." } }, { "@type": "Question", "name": "Les maladies auto-immunes augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent exacerber l'activation des récepteurs et aggraver les symptômes." } } ] } ] }

Sources (10000 au total)

Polysomnographic Predictors of Sleep, Motor, and Cognitive Dysfunction Progression in Parkinson's Disease.

Sleep disturbances are an important nonmotor feature of Parkinson's disease (PD) that can cause polysomnographic (PSG) alterations. These alterations are already present in early PD and may be associa... Nineteen longitudinal cohort studies were included. Their main findings were that (1) REM sleep behavioral events, REM sleep without atonia (RSWA), and electroencephalography (EEG) changes (mainly mic...

Acute disease induced cognitive dysfunction in older patients - an unrecognized syndrome.

It is unknown, how many older hospitalized patients experience cognitive changes independently from delirium.... In this retrospective study, cognitive function was assessed with the Montreal Cognitive Assessment on admission and discharge in 103 acute care geriatric hospital patients.... Mean age was 80.8 ± 7.3 years. The total MoCA score on admission was 17.8 (±4.5) and at discharge 17.7 (±4.4). The mean difference of the total MoCA score was - 0.1 (±3.5). 12 (11.7%) patients suffere... Cognitive changes frequently occur during acute disease of geriatric patients independently from delirium. We propose the term "acute disease induced cognitive dysfunction" (ADICD) for this entity.... German Clinical trial register (DRKS-ID: DRKS00025157 on 28.04.2021)....

Brain-immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders.

Cognitive dysfunction has been identified as a major symptom of a series of psychiatric disorders. Multidisciplinary studies have shown that cognitive dysfunction is monitored by a two-way interaction... In this review, we summarized the relevant research to uncover our comprehension of the brain-immune interaction mechanisms underlying cognitive decline.... The pathophysiological mechanisms of brain-immune interactions in psychiatric-based cognitive dysfunction involve several specific immune molecules and their associated signaling pathways, impairments... Therefore, this review may provide a better theoretical basis for integrative therapeutic considerations for psychiatric disorders associated with cognitive dysfunction....

Cognitive dysfunction in drug-naïve late-onset temporal lobe epilepsy.

To evaluate cognitive functions including memory in middle-aged and elderly patients with antiseizure drug-naïve late-onset temporal lobe epilepsy (TLE).... We performed assessments with the Wechsler Adult Intelligence Scale-III (WAIS-III) and Wechsler Memory Scale-Revised (WMS-R) in 26 antiseizure drug-naïve patients with late-onset TLE, in comparison to... Patients with epilepsy had a significantly lower score than healthy controls in the verbal intelligence quotient (IQ), the performance IQ, and full-scale IQ in intelligence testing. Patients showed si... Patients with antiseizure drug-naïve late-onset TLE displayed cognitive deficits including the domains of memory by using standard clinical neuropsychological test. Patients with late-onset epilepsy n...

Risk factors for post-COVID cognitive dysfunctions: the impact of psychosocial vulnerability.

Cognitive dysfunction is a well-established manifestation of the post-COVID syndrome. Psychological vulnerability to stressors can modify disease trajectories, causing long-term risk for negative outc... All subjects were submitted to a comprehensive neuropsychological battery and an assessment of perceived loneliness, post-traumatic stress, and changes in anxiety and depression levels. A social vulne... Forty-five percent of individuals showed cognitive impairments, with predominant memory and executive deficits. Post-traumatic stress disorder was clinically relevant in 44% of the sample. Social vuln... These findings suggest that psychosocial assessment of post-COVID patients can detect fragile individuals at risk of cognitive impairments. Dedicated psychological support services may play a useful r...

Evoked mid-frontal activity predicts cognitive dysfunction in Parkinson's disease.

Cognitive dysfunction is a major feature of Parkinson's disease (PD), but the pathophysiology remains unknown. One potential mechanism is abnormal low-frequency cortical rhythms which engage cognitive... We recruited 100 patients with PD and 49 demographically similar control participants who completed a series of cognitive control tasks, including the Simon, oddball and interval-timing tasks. We focu... We found that PD-related cognitive dysfunction was associated with increased response latencies and decreased mid-frontal delta power across all tasks. Within patients with PD, the first principal com... These data demonstrate that cue-evoked mid-frontal delta/theta rhythms directly relate to cognition in PD. Our results provide insight into the nature of low-frequency frontal rhythms and suggest that...

Cognitive dysfunction and neurometabolic alternations in major depressive disorder with gastrointestinal symptoms.

Brain biochemical abnormalities have been associated with major depressive disorder (MDD) and cognitive impairments. However, the cognitive performance and neurometabolic alterations of MDD patients a... Fifty MDD patients with GI symptoms (GI group), 46 patients without GI symptoms (NGI group) and 50 demographically matched healthy controls (HCs) underwent Measurement and Treatment Research to Improv... Compared to HCs, participants in both the GI and NGI groups had significantly reduced performance in the six MCCB cognitive domains (all p < 0.05), except for reasoning and problem solving. Higher Cho... Our findings suggest that MDD patients with GI symptoms may exhibit greater neurometabolic alternations than those without GI symptoms, while both show similar cognitive dysfunction. In addition, neur...